Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD ... and IL-13 inhibitor Dupixent (dupilumab ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do not address the multiple inflammatory pathways that cause its specific ...

Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD ... which led to the development of Dupixent, a treatment for moderate to severe AD.

Atopic dermatitis ... When used for AD, especially if it's widespread or disabling, the drugs help reduce inflammation.

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...